
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
FDA's Final Rule Forces the Pharma Industry to Change It's Clinical Trial Culture
over 25 years ago
Internet DTC - Minding Your P's & Q'sover 25 years ago
Regulation: Two-Track Planover 25 years ago
Policy: Tectonic Shiftover 25 years ago
Liberated?over 25 years ago
A Matter of Tasteover 25 years ago
Partnerships: Bargaining Biotechsover 25 years ago
Genentech's Passion for Patientsover 25 years ago
Regulation: OK After All





